PanTher Completes Dose Escalation Phase in Non-Metastatic Pancreatic Cancer Phase 1b Trial and Appoints Tim Clackson to the Board of Directors
PanTher Awarded $1.8M in Supplemental CPRIT Funding
From research to entrepreneurship: the story of Laura Indolfi. How PanTher Therapeutics was born and the vision behind a new generation of oncological treatments.
Amid the dip, biotech execs share silver linings in a tumultuous environment
